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Background: The adenomatous polyposis coli (APC) tumour suppressor gene encodes a 2843 residue (310 kDa)
protein. APC is a multifunctional protein involved in the regulation of β-catenin/Wnt signalling, cytoskeletal
dynamics and cell adhesion. APC mutations occur in most colorectal cancers and typically result in truncation of the
C-terminal half of the protein.
Results: In order to investigate the biophysical properties of APC, we have generated a set of monoclonal
antibodies which enable purification of recombinant forms of APC. Here we describe the characterisation of these
anti-APC monoclonal antibodies (APC-NT) that specifically recognise endogenous APC both in solution and in fixed
cells. Full-length APC(1–2843) and cancer-associated, truncated APC proteins, APC(1–1638) and APC(1–1311) were
produced in Sf9 insect cells.
Conclusions: Recombinant APC proteins were purified using a two-step affinity approach using our APC-NT
antibodies. The purification of APC proteins provides the basis for detailed structure/function analyses of full-length,
cancer-truncated and endogenous forms of the protein.
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The adenomatous polyposis coli (APC) gene is mutated
in the germline of individuals with familial adenomatous
polyposis (FAP) and in more than 80% of sporadic colo-
rectal cancers [1-3]. APC encodes a large, multifunctional
protein (2843 aa, 310 kDa) and contains protein-binding
domains that have implicated APC in a range of cellular
functions. APC is best characterised for its role in the
down-regulation of β-catenin and the Wnt signalling path-
way through interactions with β-catenin and Axin [4-8].
APC also functions in cytoskeletal organisation, cell mi-
gration and adhesion [9,10] via interactions with cytoskel-
etal proteins, such as tubulin, actin, EB1 and discs large
protein [11-14].
APC mutations are generally missense mutations that
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reproduction in any medium, provided the orof truncated APC proteins [1]. The majority of muta-
tions in APC are confined to a mutation cluster region
(MCR) [2] encompassing the β-catenin and Axin binding
sites. Truncation of APC disrupts key binding sites in
the C-terminus of the protein, including interactions
with the Wnt signalling proteins and both actin and
microtubule cytoskeletons. It is now established that
APC truncation leads to aberrant regulation of β-catenin
which results in increased transcription of Wnt target
genes [15,16].
Despite the importance of APC in colorectal cancer,
little is known about the biophysical properties and/or
structure of the APC protein or its cancer-truncated forms.
Limited structural information on APC has come from
studies using small fragments of APC, usually in complex
with other proteins. The N-terminus of APC was crystal-
ised as a coiled-coil dimer [17,18], and the 15 and 20 aa re-
peats were crystalised as fragments with β-catenin [19,20].
However, as these studies used small fragments rather than
the full-length APC protein, the structural differences and
implications for protein binding between full-length or the
truncated APC are not yet known.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of new APC monoclonal antibodies and their use in the
purification of recombinant forms of APC. APC mono-
clonal antibodies were generated to the N-terminus of
APC, and antibody clones were selected by a combin-
ation of ELISA, immunoprecipitation and biosensor ana-
lysis. The antibodies were then further characterised by
immunoprecipitation and immunofluorescence of en-
dogenous APC. Full length (fl-APC) and truncated APC
proteins (APC(1–1638) and APC(1–1311)) were gener-
ated using baculoviral-mediated expression in Sf9 cells
and purified using a two-step affinity strategy involving
immobilised metal affinity chromatography (IMAC) and
APC monoclonal antibodies.
Results
Generation of novel APC monoclonal antibodies
The N-terminus of APC has been shown to form a
coiled-coil structure and dimerise in solution [21]. An
N-terminal fragment of APC (residues 1–61) was used as
an antigen to raise monoclonal antibodies. This region of
APC forms a dimer (not shown) and was therefore
thought to mimic the structure of the same region in full-
length APC.
Anti-APC-NT mouse monoclonal antibodies were pro-
duced and clones were screened for immunoreactivity to
the immunizing antigen by ELISA and surface plasmon
resonance (BIAcore) (not shown). Clones that recognised
APC-NT were isotyped and analysed for their ability to im-
munoprecipitate endogenous APC from MDCK epithelial
cells (containing wild-type APC) and SW480 colorectal
carcinoma cells (containing mutated, truncated APC [22])
(Figure 1B). Both full-length (wild-type) and truncated
APC were immunoprecipitated by APC mAb clones 2E7,
6D12, 6G6, 9G11 (all IgG) and 8D9 (IgG2a) (Figure 1B).
Therefore APC-NT antibodies can be used to purify en-
dogenous APC proteins, both wild-type and cancer mu-
tated, truncated APC.
In contrast, APC-NT mAbs did not detect APC proteins
by Western blot analysis. Cell lysates from MDCK or
SW480 cells were separated by SDS-PAGE and immuno-
blotted with APC-NT or commercial APC antibodies.
Only the commercial antibody detected wild-type or trun-
cated APC proteins on immunoblots (not shown). This
suggests that APC-NT mAbs can recognise both full-
length and truncated endogenous APC in solution, sup-
porting the prediction that the antigen used had a similar
structure to the same region in endogenous, native APC.
APC-NT mAbs are unlikely to recognise a linear epitope,
as the epitope is not retained upon denaturation of en-
dogenous APC during SDS-PAGE and immunoblotting.
Recognition of a conformation-dependent epitope is likely
to contribute to the specificity of the APC-NT mAbs for
endogenous APC.These APC-NT mAbs were analysed using BIAcore
to determine whether their epitopes overlapped. Purified
APC-NT was immobilised onto a BIAcore CM5 chip and
the antibodies were injected sequentially over the immo-
bilised peptide. Binding of mAb 6D12 inhibits binding
of 6G6 and 8D9, and vice versa, suggesting they have
at least partially overlapping epitopes, but mAb 2E7 ap-
pears to bind independently of the other three antibodies
(Figure 1C), suggesting that at least 2 different epitopes on
APC-NTare recognised by the APC mAbs.
Generation of APC-encoding baculoviruses
Baculoviruses encoding fl-APC and truncated APC
proteins (APC(1–1638) and APC(1–1311)) containing
N-terminal HIS and C-terminal EE [23] affinity tags were
generated using the Bac-N-Blue system (Figure 1A). Re-
combinant APC-encoding baculoviruses were plaque-
purified and used for expression of recombinant APC in
Sf9 cells. Cells were infected at an MOI of 5 (fl-APC) or
an MOI of 1 (truncated APCs) for 72 hr which was found
to produce the highest levels of recombinant APC.
The EE-tag was inefficient for purification of the rela-
tively low levels of recombinant APC expressed by the
baculovirus. The APC-NT mAbs were therefore tested
for their ability to immunoprecipitate recombinant APC
proteins, fl-APC, APC(1–1638) or APC(1–1311) from
APC baculoviral-infected Sf9 cells (Figure 1D). In APC-
NT Ab immunoprecipitates, predominant bands were
detected at the expected molecular weights of 310, 190
and 150 kDa, respectively for fl-APC, APC(1–1638) and
APC(1–1311) (Figure 1D, left, middle and right panels,
respectively). The APC(1–1638) immunoprecipitated using
the APC mAbs 2E7 and 8D9 appeared to have a slightly
altered mobility on SDS-PAGE compared to that immuno-
precipitated with 6D12, 6G6 and 9D11. However, the con-
centrations of the antibodies in the immunoprecipitations
may differ, thus altering the apparent mobility. Taken to-
gether this data shows that each of the 5 APC-NT mAb
clones, selected for their ability to recognise endogenous
APC in solution, also recognise recombinant full-length
and truncated APC expressed in insect cells. All five APC-
NT mAbs were used to generate an APC mAb affinity
matrix by covalently cross-linking 5 mg of antibody (1 mg
each of 2E7, 6D12, 6G6, 8D9 and 9G11) to 5 ml of Protein
G-Sepharose beads.
Characterisation of APC-NT mAbs by immunofluorescence
and APC-directed siRNA treatment
We next assessed whether the APC-NT mAbs recog-
nised endogenous APC protein by immunofluorescence.
APC-NT mAb staining in MDCK cells was analysed by
confocal microscopy and compared to a commercially
available APC antibody (anti-APC-H290). In subconfluent
epithelial cells, APC decorates the ends of microtubules at
Figure 1 APC-NT mAbs recognize endogenous and recombinant full-length and truncated APC proteins in solution. A) Schematic
diagram of structures of recombinant APC proteins. The APC-NT antigen (APC residues 1–61 with an N-terminal FLAG-tag) was expressed and
purified from E.coli and used to generate the APC-NT mAbs. Full-length (fl-APC) and truncated recombinant APCs APC(1–1638) and APC(1–1311)
were expressed in Sf9 cells with N-terminal HIS and C-terminal EE tags. The protein domains of APC are indicated: Oligomerisation, Armadillo
repeats, 15 aa repeats, 20 aa repeats, SAMP motifs, basic rich domain, PDZ domain. Note: the EE-epitope tag was not used for the final affinity
purification. B) Immunoprecipitation of endogenous full-length and truncated APC. APC-NT mAb immunoprecipitates from MDCK cells (1 mg
protein, left panel) and SW480 colorectal carcinoma cells (1 mg protein, right panel) were immunoblotted (IB) with anti-APC H290. C) Biosensor
analysis shows overlapping and non-overlapping epitopes for the APC-NT mAbs. I) Representative sensorgram showing sequential injection of
APC-NT mAbs and binding to APC-NT antigen. II) Stack graph showing increases in binding (RU) to APC-NT antigen upon sequential injections
with different APC-NT mAb clones. Four combinations of APC-NT mAb clones injected sequentially are represented by shaded areas (A-D).
Column A corresponds to the sensorgram in I). 2E7 and 8D9 have different epitopes whereas 6D12 and 6G6 share overlapping epitopes.
D) Immunoprecipitation of recombinant APC proteins expressed in Sf9 cells. APC-NT mAb (2 μg) immunoprecipitates from Sf9 cell lysates
(2×107 cells) expressing fl-APC (left), APC(1–1638) (middle) or APC(1–1311) (right) were resolved by SDS-PAGE and immunoprecipitated
proteins were visualised with Coomassie blue. Note protein immunoprecipitated by 6D12 and 6G6 migrate slightly differently. The relative
positions of the molecular markers are indicated.
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Figure 2 APC-NT mAbs specifically detect APC at the ends of
microtubules. A) MDCK cells transfected with control siRNA (top) or
APC siRNA (bottom) were immunostained for APC (APC-NT mAb,
6D12 (red)) and β-tubulin (green). Distinct clusters of APC at the
ends of microtubules (arrowheads) are detected by the APC-NT
mAb in control but not APC depleted cells, scale bar 20 μm.
Enlarged view of insets is shown (right, merged image (left) and
single channel grayscale for APC (right)). Shown are single section
confocal images, scale bar 5 μm. B) Depletion of cellular APC by
siRNA. APC levels following siRNA transfection were assessed by
immunoblot analysis (with H290 Ab from Santa Cruz) in cell lysates.
Tubulin was used as a loading control. Numbers below blot are the
normalised ratio of APC protein compared to control siRNA. The
relative positions of molecular weight markers are indicated. C) SW480
CRC cells were immunostained for APC (APC-NT) and costained with
DAPI. APC staining is diffusely cytosolic and is not detected in clusters
at the ends of microtubules. Shown are single channel grayscale image
for APC (left) and merged image (APC, red and DAPI blue), scale
bar 20 μm.
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each demonstrated the expected staining pattern with con-
centrated clusters at the ends of microtubule (Figure 2A,
representative image shown for mAb 6D12). All APC anti-
bodies recognize APC at microtubule protrusions, however
only APC H290 demonstrated nuclear staining and none
of the antibodies detected APC at the centrosomes.
We confirmed the specificity of APC-NT antibodies by
comparing their immunofluorescent staining pattern in
MDCK cells treated with control siRNA with those in
which APC levels were depleted using APC-specific siR-
NAs. Transfection of MDCK cells with siRNAs targeting
APC reduced the level of APC by 70% (Figure 2B). APC
staining was still detectable in a proportion of cells, pre-
sumably reflecting residual APC protein. However, the
typical staining of APC at the ends of microtubules was
absent in the majority of APC siRNA transfected cells
for each APC-NT mAb (Figure 2A, representative image
for APC-NT 6D12). Thus each of the APC-NT mAbs
specifically recognise endogenous APC localised in clus-
ters at the ends of microtubules.
We next investigated the distribution of APC in SW480
CRC cells with the APC-NT antibodies (Figure 2C, repre-
sentative image for APC-NT 6G6). In contrast to cells ex-
pressing full-length wild-type APC, the truncated APC
protein in SW480 cells was not detected at the ends of mi-
crotubules but instead was diffusely cytosolic with some
concentration of staining in the perinuclear region. This
distribution is consistent with the loss of mictrotubule
binding in truncated APC and concomitant alterations in
cell migration that occur upon APC mutation.
Purification of recombinant APC proteins
Having confirmed the specificity of the APC-NT mAbs,
a two-step purification scheme for recombinant APC
was developed (Figure 3A). Recombinant fl-APC, APC
(1–1638) or APC(1–1311) was first purified from clarified
Sf9 cell lysates by IMAC. Fractions from this step con-
tained a predominant band at the expected molecular
weight as well as a number of minor bands (Figure 3B, left
panels). The fractions containing recombinant APC were
purified further using APC-NT mAb affinity chromatog-
raphy. To ensure maximal binding efficiency, the pooled
fractions were re-circulated over the APC-NT mAb col-
umn three times. Recombinant APC was eluted by dis-
rupting the APC: antibody interaction using low pH.
Fractions from this step also contained a predominant
band at the expected molecular weight and the levels of
minor bands were reduced (Figure 3B, right panels). The
fractions containing recombinant APC were pooled for
further analysis.
Purified recombinant APC was estimated to be ≥ 80%
pure (Figure 3C). The yield of recombinant APC protein
was estimated from the intensity of the Coomassie-blue-
Figure 3 Purification of recombinant APC proteins by a two-step method using IMAC and APC-NT mAb affinity chromatography.
A) Schematic diagram depicting the purification scheme used to purify recombinant APC proteins. B) Purification of recombinant APC proteins.
Sf9 cells (2×109) infected with either fl-APC, APC(1–1638) or APC(1–1311) were and purified using Ni-NTA resin. Proteins were eluted using a
stepwise gradient of 20, 50, 100 and 250 mM imidazole. 1% of each fraction was resolved using 4-12% Bis-Tris SDS-PAGE and stained with
Coomassie blue (Left panel, 1 = 20 mM, 2 = 50 mM, 3 = 100 mM, 4 = 250 mM). Pooled fractions containing APC were applied to a 5 ml APC-NT
mAb column and eluted with 0.1 M Glycine pH 3 in 5× 2 ml fractions (right). 1% of each fraction was resolved as above. The expected sizes of
APC proteins are indicated by arrows and relative positions of molecular weight markers in kDa are indicated. C) Purified recombinant APC
proteins. APC proteins were purified using the optimized strategy (A). The amount of APC was estimated by comparison to a band representing 1 μg
BSA. The expected size of APC proteins are indicated by arrows and relative positions of molecular weight markers are indicated. Purified APC bands were
excised and analysed using LC-MS/MS. MASCOT Protein score [26], peptide number, and amino acid coverage are indicated for each protein.
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intensity of a band representing 1 μg BSA (Figure 3C).
The amount of recombinant APC purified from 2×109
Sf9 cells was estimated to be 15, 250 and 200 μg for fl-
APC, APC(1–1638) and APC(1–1311), respectively. The
amount of fl-APC purified reflects the low expression
levels relative to the expression levels of APC(1–1638)
and APC(1–1311).
The identities of the purified recombinant APC proteins
were confirmed using LC-MS/MS (Figure 3C). Each ex-
cised gel band contained peptides matching human APC
(UniProt Accession number P25054). For fl-APC, 54 pep-
tides derived from APC spanning residues 12–2581 (24%
sequence coverage) were identified (Figure 3C) with a
MASCOT protein score of 3179. For APC(1–1638), 42
peptides were identified spanning residues 12–1617 (40%
sequence coverage, MASCOT protein score 1676) and 39
peptides spanning residues 25–1239 (51% sequence cover-
age, MASCOT protein score 2298) were identified for
APC(1–1311). Other proteins identified (other than tryp-
sin and keratin) had MASCOT scores of <70, indicatingthat levels of co-purifying proteins were not significant.
The MS data confirmed that the purified recombinant
proteins were the expected APC proteins.
Discussion
The present study demonstrates the generation of APC
mAbs that specifically recognise recombinant forms
of APC, endogenous APC in solution and the location
of APC in fixed cells. Our prediction that using a pro-
tein fragment encompassing the N-terminal oligomer-
isation domain of APC as the immunising antigen would
generate antibodies that specifically recognise native,
folded APC was correct: each of the APC-NT mAbs re-
cognised native APC. The coiled-coil region was there-
fore a good antigen for raising monoclonal antibodies
that can be used for isolation and detection of en-
dogenous or recombinant, full-length or truncated APC.
The APC-NT mAb clones recognized different epitopes
and so we used a combination of the five APC-NT mAbs
to develop an efficient affinity purification of recombin-
ant APC.
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teristic clusters at the ends of microtubules in epithelial
cells, which is consistent with the previously reported
subcellular localisation of APC [24,25,27]. However, in
contrast to a commercial APC antibody (H290), none of
our APC-NT mAb clones stained the nucleus. There has
been some controversy regarding the specificity of com-
monly used APC antibodies [28]. One APC antibody
that was used to show nuclear localisation of endogen-
ous APC was subsequently shown to cross-react with
the DNA binding protein Ku80 [29]. Another report
used biochemical fractionation and fluorescence micros-
copy to compare the localisation of APC as detected by
a panel of the most commonly used APC antibodies,
and found that most of the antibodies tested were un-
able to specifically detect APC in the nucleus [30]. In
SW480 CRC cells that express truncated APC protein,
the distribution was diffusely cytoplasmic, consistent with
loss of the C-terminal microtubule binding regions of
APC. Results from the five APC-NT mAbs reported here
support the concept that endogenous APC is predomin-
antly localised at the ends of microtubules in epithelial
cells containing wild-type APC, a distribution that is lost
upon APC truncation.
Conclusions
In this study, the APC-NT mAbs were used for the puri-
fication of recombinant full-length and truncated APC.
Recombinant APC that has been purified by this method
can be used for further analysis of APC biochemistry. As
these antibodies have been shown to recognise specific-
ally endogenous, native APC, they will also be useful for
the study of APC in cells and tissue samples, and for the
isolation of APC-containing protein complexes in normal
and cancer cells. These reagents will be useful for under-
standing the structure/function relationships of full-length
and truncated APC and the interactions of APC with
other cellular proteins.
Methods
Generation of APC monoclonal antibodies
APC monoclonal antibodies (APC-NT mAbs) were raised
against a fragment of human APC (amino acids 1–61)
(accession number P25054) with an N-terminal FLAG
epitope tag, produced in E.coli (APC-NT). The frag-
ment was amplified (Forward: 5′-CGCATATGTGCGA
TTACAAGGATGACGACGATAAGGGGGGGGCTATG
GCTGCAGCTTCGTATGATC-3′, Reverse: 5′-GGCTG
GATCCTTAAGCCATAGCTTCATC-3′) and cloned into
pET30a + for E.coli expression. APC-NT was purified by
affinity chromatography on anti-FLAG (M2) Sepharose
beads (Sigma) followed by anion exchange (MonoQ
HR10/10, GE Healthcare) and reversed-phase HPLC
(Discovery C18 4.6 mm i.d. × 100 mm, Supelco).Mice were immunised with 3× 30 μg purified APC-
NT. Immunisation of mice, fusion of mouse spleens for
production of hybridomas and initial screening for APC-
NT mAbs was carried out by the WEHI Monoclonal
Antibody Facility (Bundoora, Australia). Hybridomas were
screened further for binding to the APC-NT antigen by
ELISA and BIAcore analysis. Five clones (clones 2E7,
6D12, 6G6, 8D9, 9G11) were selected and purified by
Protein-A chromatography. Antibodies were isotyped using
Isostrip isotyping antibody kit (Roche).
Immunoprecipitation of endogenous APC protein
MDCK cells [31] were grown in DMEM supplemented
with 10% foetal calf serum and 1% penicillin/streptomycin.
Colorectal carcinoma SW480 cells [22] were grown
in RPMI supplemented with 0.01 μg/ml thioglycerol,
0.025 U/ml insulin, 1 μg/ml hydrocortisone, 10% FCS and
1% penicillin/streptomycin. Immunoprecipitations were
performed as described [27]. Briefly, clarified cell lysates
(1 mg) were incubated with APC-NT mAbs (2 μg) for 16 h
at 4°C and precipitated with Protein G-Sepharose (100 μl,
10% slurry) (GE Healthcare) for 30 min at 4°C. Eluted pro-
teins were analysed by SDS-PAGE (3–8% Tris Acetate
NuPAGE gels) (Novex) and detected using anti-APC H290
antibody (Santa Cruz) followed by anti-rabbit IRDye800
antibody (LiCor) and imaged with the Odyssey infrared im-
aging system (LiCor).
Biosensor analysis
All experiments were performed on BIAcore biosensor
2000 (BIAcore). APC-NT protein was exchanged into
10 mM NaAc pH 4.5 and immobilised on a CM5 chip
using NHS-EDC as described previously [32]. Multi-
determinant binding analysis was performed at a con-
stant flow rate of 20 μl/min for 50 μl samples of each
APC-NT antibody sequentially, as shown.
Construction and expression of recombinant APC proteins
Fl-APC was cloned into the pBlueBacHIS2a in three frag-
ments: Firstly, the 5′ end (1–617 bp) was PCR amplified to
include a SacI site (Forward: 5′-GGTGGTGAGCTCATG
GCTGCAGCTTCATATG-3′, Reverse: 5′-GGAAGAAC
AACTAGGTACCTGCCAGG-3′) and cloned into pGEM
(Invitrogen). Secondly, the mid-region (618–6708 bp) was
subcloned by digestion with KpnI and BstBI from pET30a-
myc-APC [33]. Finally, the 3′ end (6709–8532 bp) was
amplified by PCR to include a spacer, EE-tag [34] and
SalI site (Forward: 5′-CTCCAACCAACAATCAGC-3′,
Reverse: 5′-TACCTTGTGACATCTGTTCCCGGGGG
GGAGTTCATGCCGATGGAGTGAGTCGACGGATC-
CATCC-3′) and cloned into pGEM. Each fragment
was subcloned sequentially (SacI-KpnI, KpnI-BstBI,
BstBI-SalI) into pBlueBacHIS2a.
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in two fragments. Firstly, the 5′ end (1–2156 bp) was amp-
lified to include a 5′ SacI and a 3′ NcoI site (Forward:
5′-GGTGGTGAGCTCATGGCTGCAGCTTCATATG-3′,
Reverse: 5′-GCACAAAATGATTGCC ATGGACCAC
C-3′) and cloned into pGEM. Separate 3′ ends were gen-
erated by PCR and cloned into pGEM for APC(1–1638)









fragment was subcloned sequentially (SacI-NcoI, NcoI-
SalI) into pBlueBacHIS2a.
pBlueBacHIS2a-APC cDNAs were co-transfected into
Sf9 cells with linearised Bac-N-Blue™ DNA (Invitrogen).
The resulting recombinant baculoviruses were plaque
purified and amplified as described [35]. Sf9 (2×107 cells)
were infected with recombinant baculoviruses at a multi-
plicity of infection (MOI) between 1 and 5 pfu/ml to de-
termine the optimum MOI for protein expression.
Immunoprecipitation of recombinant proteins
Sf9 cells (2×107 cells) were infected with the indicated
baculoviruses at the optimised MOI. Cells were lysed in
Triton X-100 (TX-100) Lysis buffer (Phosphate Buffered
Saline (PBS) containing 1% TX-100 (Sigma) and prote-
ase inhibitors (Complete™ Protease Inhibitor Cocktail
(Roche)) (500 μl). Lysates were clarified by centrifugation
at 16000 × g for 10 min at 4°C and immunoprecipitated as
described above.
siRNA treatment and immunofluorescence
APC was depleted from MDCK cells using RNA inter-
ference as described [27]. MDCK and SW480 cells were
lysed for immunoblot analysis or fixed for immunofluor-
escence as described [27]. Immunofluorescent staining
was detected in successive focal planes using an Olym-
pus FV1000 or Nikon C1 confocal microscope equipped
with an Olympus 60× (NA 1.35) oil immersion lens or
Nikon 60× NA1.35) water immersion lens using stand-
ard filter sets and laser lines.
Affinity purification of recombinant APC
Sf9 cells (2×109 cells) were infected with recombinant
baculoviruses, harvested after 72 hrs, and lysed in TX-
100 Lysis buffer + 20 mM imidazole. Recombinant APC
proteins were affinity purified using IMAC on 1 ml Ni-
NTA agarose (QIAgen) equilibrated in 20 mM imid-
azole, 2 mM β-mercaptoethanol in PBS, pH 7.5. Unboundproteins were removed with 20-column volumes of the
same buffer. Bound APC was eluted with a step gradient
of 5 ml 50 mM imidazole, 2.5 ml 100 mM imidazole
and 2.5 ml 250 mM imidazole in the same buffer. Frac-
tions were analysed by SDS-PAGE and Coomassie blue
staining.
Recombinant APC was further purified by affinity chro-
matography using a mixture of the 5 APC-NT mAbs. Puri-
fied APC-NT mAbs (2E7. 6D12. 6D6, 8D9 and 9D11 5 mg
total, 1 mg/clone) were covalently conjugated to Protein
G-Sepharose (1 mg Ab/ml) using 50 mM Dimethyl Pimili-
midate (Pierce) [36]. Coupling efficiency was determined
by SDS-PAGE and Bradford assay, as previously described
[36]. The APC-containing fractions from the Ni-NTA step
were applied to APC-NT mAb Sepharose equilibrated with
PBS containing 2 mM β-mercaptoethanol and 0.5 mM
PMSF. Unbound proteins were removed with 20-column
volumes of the same buffer. Bound APC proteins were
eluted from the antibody column with two column vol-
umes of 0.1 M Glycine, pH 3 containing 0.5 mM PMSF.
Fractions (2 ml) were neutralised immediately with 1 M
Tris, pH 8 and analysed by SDS-PAGE as above.Mass spectrometry
Coomassie blue-stained bands were excised from SDS-
PAGE gels and digested in-gel with trypsin [37]. The
resulting peptides were analysed by liquid chromato-
graph coupled to tandem mass spectrometry (LC-MS/MS)
(LCQ-DECA, ThermoFinnigan) as described previously
[37]. Peak lists were extracted as previously described [37]
and searches performed against the LudwigNR protein se-
quence database (version Q209) (http://www.ludwig.edu.
au/archive) using Mascot (version 2.2.04, Matrix Science)
with settings of trypsin as the protease, carbamido-cysteine
as fixed modification and oxidation of methionine and
N-terminal acetylation as variable modifications. All as-
signments to APC were confirmed by manual inspection
of the MS/MS spectra taking into account the Mascot ions
score as well as the expectation value. Those peptide spec-
tral matches falling below Mascot’s Identity or Homology
threshold were accepted only if the annotated spectrum
was in accordance with the known rules for peptide frag-
mentation (Eugene Kapp, personal communication).Abbreviations
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